Jazz Pharmaceuticals Reports Quarterly Results for Period Ended June 30, 2026

What Happened

• On August 3, 2026, Jazz Pharmaceuticals plc announced and furnished a press release reporting its financial results for the quarter ended June 30, 2026. The press release was filed as Exhibit 99.1 to the Form 8-K under Item 2.02 (Results of Operations and Financial Condition). The report was signed on behalf of the company by Philip L. Johnson, Executive Vice President and Chief Financial Officer.

Key Details

• Filing date: August 3, 2026 (Form 8-K).
• Period covered: quarter ended June 30, 2026.
• Press release: furnished as Exhibit 99.1 to the 8-K (contains the detailed earnings and financial metrics).
• Authorized signatory: Philip L. Johnson, EVP & CFO.

Why It Matters

• This 8-K notifies investors that Jazz has publicly released its latest quarterly earnings and financial condition; the accompanying press release will contain the specific revenue, earnings, and any forward-looking commentary. Investors should review Exhibit 99.1 (the press release) for the detailed figures and any changes to guidance or material financial metrics that could affect valuation or trading decisions.